245 related articles for article (PubMed ID: 21798853)
21. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.
Nakagawa S; Sakamoto Y; Okabe H; Hayashi H; Hashimoto D; Yokoyama N; Tokunaga R; Sakamoto K; Kuroki H; Mima K; Beppu T; Baba H
Oncol Rep; 2014 Feb; 31(2):983-8. PubMed ID: 24337160
[TBL] [Abstract][Full Text] [Related]
22. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells.
Tan J; Yang X; Zhuang L; Jiang X; Chen W; Lee PL; Karuturi RK; Tan PB; Liu ET; Yu Q
Genes Dev; 2007 May; 21(9):1050-63. PubMed ID: 17437993
[TBL] [Abstract][Full Text] [Related]
23. Determinants of sensitivity to DZNep induced apoptosis in multiple myeloma cells.
Xie Z; Bi C; Cheong LL; Liu SC; Huang G; Zhou J; Yu Q; Chen CS; Chng WJ
PLoS One; 2011; 6(6):e21583. PubMed ID: 21720561
[TBL] [Abstract][Full Text] [Related]
24. DNA methyltransferase controls stem cell aging by regulating BMI1 and EZH2 through microRNAs.
So AY; Jung JW; Lee S; Kim HS; Kang KS
PLoS One; 2011 May; 6(5):e19503. PubMed ID: 21572997
[TBL] [Abstract][Full Text] [Related]
25. S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition.
Hayden A; Johnson PW; Packham G; Crabb SJ
Breast Cancer Res Treat; 2011 May; 127(1):109-19. PubMed ID: 20556507
[TBL] [Abstract][Full Text] [Related]
26. Anti-leukemic effects of HDACi Belinostat and HMTi 3-Deazaneplanocin A on human acute promyelocytic leukemia cells.
Valiulienė G; Stirblytė I; Jasnauskaitė M; Borutinskaitė V; Navakauskienė R
Eur J Pharmacol; 2017 Mar; 799():143-153. PubMed ID: 28192098
[TBL] [Abstract][Full Text] [Related]
27. Histone H3 modifications associated with differentiation and long-term culture of mesenchymal adipose stem cells.
Noer A; Lindeman LC; Collas P
Stem Cells Dev; 2009 Jun; 18(5):725-36. PubMed ID: 18771397
[TBL] [Abstract][Full Text] [Related]
28. The polycomb repressive complex 2 is a potential target of SUMO modifications.
Riising EM; Boggio R; Chiocca S; Helin K; Pasini D
PLoS One; 2008 Jul; 3(7):e2704. PubMed ID: 18628979
[TBL] [Abstract][Full Text] [Related]
29. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep).
Cheng LL; Itahana Y; Lei ZD; Chia NY; Wu Y; Yu Y; Zhang SL; Thike AA; Pandey A; Rozen S; Voorhoeve PM; Yu Q; Tan PH; Bay BH; Itahana K; Tan P
Clin Cancer Res; 2012 Aug; 18(15):4201-12. PubMed ID: 22675170
[TBL] [Abstract][Full Text] [Related]
30. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.
Avan A; Crea F; Paolicchi E; Funel N; Galvani E; Marquez VE; Honeywell RJ; Danesi R; Peters GJ; Giovannetti E
Mol Cancer Ther; 2012 Aug; 11(8):1735-46. PubMed ID: 22622284
[TBL] [Abstract][Full Text] [Related]
31. A proteasome inhibitor-stimulated Nrf1 protein-dependent compensatory increase in proteasome subunit gene expression reduces polycomb group protein level.
Balasubramanian S; Kanade S; Han B; Eckert RL
J Biol Chem; 2012 Oct; 287(43):36179-89. PubMed ID: 22932898
[TBL] [Abstract][Full Text] [Related]
32. pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4alpha tumor suppressor gene.
Kotake Y; Cao R; Viatour P; Sage J; Zhang Y; Xiong Y
Genes Dev; 2007 Jan; 21(1):49-54. PubMed ID: 17210787
[TBL] [Abstract][Full Text] [Related]
33. Regulation of CD11b transcription by decreasing PRC2 and increased acH4 level during ATRA-induced HL-60 differentiation.
Tang H; Chen F; Tan Q; Tan S; Liu L; Zhang F
Acta Biochim Biophys Sin (Shanghai); 2009 Jul; 41(7):588-93. PubMed ID: 19578722
[TBL] [Abstract][Full Text] [Related]
34. Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells.
Sun F; Chan E; Wu Z; Yang X; Marquez VE; Yu Q
Mol Cancer Ther; 2009 Dec; 8(12):3191-202. PubMed ID: 19934278
[TBL] [Abstract][Full Text] [Related]
35. Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27.
Kirmizis A; Bartley SM; Kuzmichev A; Margueron R; Reinberg D; Green R; Farnham PJ
Genes Dev; 2004 Jul; 18(13):1592-605. PubMed ID: 15231737
[TBL] [Abstract][Full Text] [Related]
36. (-)-Epigallocatechin-3-gallate reverses the expression of various tumor-suppressor genes by inhibiting DNA methyltransferases and histone deacetylases in human cervical cancer cells.
Khan MA; Hussain A; Sundaram MK; Alalami U; Gunasekera D; Ramesh L; Hamza A; Quraishi U
Oncol Rep; 2015 Apr; 33(4):1976-84. PubMed ID: 25682960
[TBL] [Abstract][Full Text] [Related]
37. HDAC inhibitors conquer Polycomb proteins.
Yaswen P
Cell Cycle; 2010 Jul; 9(14):2705. PubMed ID: 20676029
[No Abstract] [Full Text] [Related]
38. Green tea polyphenol EGCG causes anti-cancerous epigenetic modulations in acute promyelocytic leukemia cells.
Borutinskaitė V; Virkšaitė A; Gudelytė G; Navakauskienė R
Leuk Lymphoma; 2018 Feb; 59(2):469-478. PubMed ID: 28641467
[TBL] [Abstract][Full Text] [Related]
39. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions.
Bracken AP; Dietrich N; Pasini D; Hansen KH; Helin K
Genes Dev; 2006 May; 20(9):1123-36. PubMed ID: 16618801
[TBL] [Abstract][Full Text] [Related]
40. EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression.
Fan T; Jiang S; Chung N; Alikhan A; Ni C; Lee CC; Hornyak TJ
Mol Cancer Res; 2011 Apr; 9(4):418-29. PubMed ID: 21383005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
